Radioactive prostate cancer drug given NHS go-ahead
Radium-223 dichloride approved for patients whose cancer has spread to the bones, but who are too weak to undergo chemotherapy
A radioactive prostate cancer drug has been recommended for routine NHS use following a decision by the National Institute for Health and Care Excellence (Nice).
Radium-223 dichloride, marketed as Xofigo, could be made available for treating prostate cancer patients as early as December.
Guardian
Continue reading...
No comments:
Post a Comment